2025 Trump Tariffs on Pharmaceutical Imports

Trump announces soon-to-be tariffs on pharmaceutical imports, we dig into how much Novo Nordisk and Eli Lilly could be affected.

Once a year GLP1? Exploring Semaglutide implants

GLP1 implants that are administered once or twice a year and deliver consistent Semaglutide, powered by Vivani Medical's NanoPortal technology.

Hims pivots to branded Tirzepatide, generic Liraglutide

Hims changes to selling branded Tirzepatide along with the Liraglutide generic on their telehealth platform, after the shortage ends.

STRIDE study: GLP1s vs peripheral artery disease (PAD)

Walk farther with GLP1s -- results from the STRIDE study show Semaglutide effective for treating Peripheral Artery Disease (PAD)

Novo Nordisk licenses GLP1 drug from United BioTechnology, a Chinese research firm

Novo Nordisk licenses the right to sell a new GLP1 being developed in China -- 15% weight loss in 12 weeks (in an admittedly small study).

Novo Nordisk offers cheaper Wegovy

Novo Nordisk makes available cheaper Wegovy, via it's savings plan, purchasable at local pharmacies.

VK2735's manufacturing alliance with CordenPharma

Viking secures a manufacturing alliance with CordenPharma, promising "metric tons" of production of VK2735

BRP - a new GLP1-like peptide

We dive into BRP, a possible new future for GLP1-like formulation that could be even more beneficial without the downsides.

HIMS ends compounded Semaglutide offering

Hims announces it will stop providing compounded Semaglutide, after removal from the FDA shortage list.

Semaglutide removed from shortage list

It happened sooner than we expected -- the FDA has announced Semaglutide shortage resolution, removing it from the shortage list.

Mexico and GLP1s

We explore GLP1 medical tourism, supply issues, and adoption of generic GLP1 Receptor Agonists in Mexico.

Shortages threaten corporate profits, likely to end soon

We think the GLP1 shortage is going to end in the first half of 2025. Here's why.